Deerfield Beach, FL -- (SBWIRE) -- 07/06/2016 -- Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is also known as silent liver disease. It is a type of nonalcoholic fatty liver disease (NAFLD), which mainly affects people with diabetes and obesity. Nonalcoholic Steatohepatitis (NASH) is defined by histological hallmarks of inflammation, hepatic steatosis, cell death, and fibrosis. A number of drugs used to treat medical situation have been NASH, such as amiodarone (Corderone, Pacerone), tamoxifen (Nolvadex), perhexiline maleate (Pexhid) and steroids (eg, prednisone). Medical studies have identified a strong connection of NASH with certain risk factors such as insulin resistance, oxidative stress and release of toxic inflammatory proteins.

Nonalcoholic steatohepatitis is a gradually becoming common chronic liver disease around the world and is closely related with diabetes and obesity. Rising incidence of NAFLD cases, changing lifestyle patterns, increasing rate of obesity and diabetes, and initiatives for research and development are the major driving factors of this market. However, insufficient information about the pathophysiology of NASH tissue and ineffective diagnostic technology for NASH is considered to restraint in this market.

Read MOre @  http://www.syndicatemarketresearch.com/market-analysis/nonalcoholic-steatohepatitis-market.html

The report includes detailed competitive landscape of the global nonalcoholic steatohepatitis market and an analysis of Porter's five forces model for the nonalcoholic steatohepatitis market has also been included. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the nonalcoholic steatohepatitis market based on drugs type and region segment. GFT505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Poglitazone, Placebo is the drug type segment of nonalcoholic steatohepatitis market.

Major regional segments analyzed in this study include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa with its further bifurcation into major countries including U.S., Germany, France, UK, China, Japan, India, and Brazil.  This segmentation includes demand for nonalcoholic steatohepatitis based on individual products and applications in all the regions and countries. The nonalcoholic steatohepatitis market is dominated by North America followed by Asia Pacific. Asia pacific is expected to the fastest growing segment in the forecast period.

The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Intercepts Pharmaceuticals, Exalenz Bioscience Inc.,  Galectin Therapeutics Inc., Genfit, Gilead Science, AstraZeneca plc, Echosense SA, Raptor Pharmaceutical Corp,  Matinas Biopharma Holdings Inc., Enzo Biochem, Inc., Galmed Pharmaceuticals Ltd.,  Perspectum Diagnostics and Novo Nordisk.

Sample Report @  http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=52719

This report segments the global nonalcoholic steatohepatitis market as follows:

Global Nonalcoholic Steatohepatitis Market: Drug Type Segment Analysis

- GFT505
- Obeticholic Acid (INT-747)
- Simtuzumab and Liraglutide (Victoza)
- Vitamin E
- Poglitazone
- Placebo

Global Nonalcoholic Steatohepatitis Market: Regional Segment Analysis

- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East And Africa

Contact US:
Joel John
3422 SW 15 Street,Suit #8138
Deerfield Beach,Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Email: sales@syndicatemarketresearch.com
Website: http://www.syndicatemarketresearch.com/